Non-injection Drug Use and Injection Initiation Assistance among People Who Inject Drugs in Tijuana, Mexico

Amen Ben Hamida · Claudia Rafful · Sonia Jain ·
Shelly Sun · Patricia Gonzalez-Zuniga ·
Gudelia Rangel · Steffanie A. Strathdee · Dan Werb

Published online: 16 August 2017
© The New York Academy of Medicine 2017

Abstract Although most people who inject drugs (PWID) report receiving assistance during injection initiation events, little research has focused on risk factors among PWID for providing injection initiation assistance. We therefore sought to determine the influence of non-injection drug use among PWID on their risk to initiate others. We used generalized estimating equation (GEE)

models on longitudinal data among a prospective cohort of PWID in Tijuana, Mexico (*Proyecto El Cuete IV*), while controlling for potential confounders. At baseline, 534 participants provided data on injection initiation assistance. Overall, 14% reported ever initiating others, with 4% reporting this behavior recently (i.e., in the past 6 months). In a multivariable GEE model, recent non-injection drug use was independently associated with providing injection initiation assistance (adjusted odds ratio [AOR] = 2.42, 95% confidence interval [CI] = 1.39–4.20). Further, in subanalyses examining specific drug types, recent non-injection use of cocaine (AOR = 9.31, 95% CI = 3.98–21.78), heroin (AOR = 4.00, 95% CI = 1.88–8.54), and methamphetamine (AOR = 2.03, 95% CI = 1.16–3.55) were all significantly associated with reporting providing injection initiation assistance. Our findings may have important implications for the development of interventional approaches to reduce injection initiation and related harms. Further research is needed to validate findings and inform future approaches to preventing entry into drug injecting.

A. Ben Hamida · C. Rafful · P. Gonzalez-Zuniga ·
S. A. Strathdee · D. Werb
Division of Global Public Health, University of California San
Diego, San Diego, CA, USA

A. Ben Hamida · C. Rafful
Graduate School of Public Health, San Diego State University, San
Diego, CA, USA

S. Jain · S. Sun
Department of Family Medicine and Public Health, Biostatistics
Research Center, University of California San Diego, San Diego,
CA, USA

G. Rangel
Secretariat of Health, Mexico City, Mexico

G. Rangel
Mexico-United States Border Health Commission, El Paso, TX,
USA

D. Werb
Centre for Urban Health Solutions, St. Michael's Hospital,
Toronto, ON M5B 1W8, Canada

D. Werb (✉)
University of California School of Medicine, 9500 Gilman Drive,
La Jolla, CA 92093-0507, USA
e-mail: dwerb@ucsd.edu

Keywords Injection initiation · Injection drug use ·
People who inject drugs · Non-injection drug use ·
Tijuana · Border health · Prevention

Introduction

Twelve million people are estimated to inject drugs worldwide [1]. People who inject drugs (PWID) are more susceptible to human immunodeficiency virus (HIV)

transmission compared with other adults [2], leading to an estimated 1.6 million HIV-seropositive PWID worldwide [1]. Hepatitis C virus (HCV) is also a significant cause of morbidity among PWID, with an estimated 6 million PWID worldwide believed to be HCV-seropositive [1], which represents a leading cause of death among this population, particularly among those co-infected with HIV [3–6]. Furthermore, PWID are exposed to a higher risk of cutaneous infections [7], infective endocarditis [8], and fatal drug overdose [9]. Given these many harms, experts have increasingly focused on preventing the initiation of injection drug use itself as a way to reduce the risk of a variety of negative health and social outcomes [10–12]. Data suggest that street-involved youth may progress quickly to regular injection drug use after the first experimentation with injecting [13], and that the risk of acquiring HIV, HCV, and other blood-borne pathogens is very high within the first few months and years after injection initiation [14–18]. As such, preventing entry into injection drug use is increasingly seen as a public health priority [10–12, 19].

Tijuana, Baja California, is a Mexican city situated on the western Mexico-USA border, on a major migration and drug trafficking route [20] stretching from the coca-producing Andean region in South America to Canada. Tijuana's location along this route has made it particularly vulnerable to a range of drug-related problems. In 2003, for instance, it was estimated that about 6000 PWID injected in semi-public settings such as “shooting galleries” in the city [21] although the total PWID population is likely closer to 10,000 [22]. Studies conducted in Tijuana have estimated HIV prevalence at 4% [22] as well as an HIV incidence rate of 2.18 per 100 person-years among PWID [23].

To date, research on injection initiation has largely focused on the characteristics and circumstances of first injection events largely from the perspective of the individual being initiated [24]. Importantly, having peers, friends, or intimate partners who inject drugs has been repeatedly shown to be a risk factor for injection initiation [14, 25–31]. However, fewer studies have investigated the specific characteristics of persons who already inject drugs and who provide initiation assistance to others, despite the fact that the majority of sampled PWID report receiving assistance with their first injection [26, 32]. While more research is needed, individual characteristics identified as possible risk factors for initiating other people into injection include being unemployed [32, 33], having described how to inject to non-injectors [34],

having ever spoken positively about injecting to a non-injector [32], having been in prison or detention [35], and having obtained needles and syringes from informal sources such as friends and dealers [35]. However, existing studies have also been limited by small sample sizes [32] and cross-sectional designs [26, 32–35].

Non-injection drug use generally precedes injection initiation, with some drugs, such as heroin [14, 31], cocaine [14, 31], methamphetamine [36], and certain opioids [37, 38] shown to be associated with this transition among injection-naïve drug users. However, there remain knowledge gaps regarding the impact that the use of non-injection drugs by PWID may have on their risk of initiating others into injecting, particularly in settings characterized by large high-risk drug-using populations. Indeed, to our knowledge, only one cross-sectional study has investigated this topic, finding that recent non-injection powder cocaine use among PWID in California was associated with providing injection initiation assistance [34]. We therefore sought to investigate the impact of non-injection drug use on the risk of providing injection initiation assistance among a prospective cohort of PWID in Tijuana, Mexico. We hypothesized that non-injection drug use among PWID is associated with higher rates of injection initiation.

Methods

Preventing Injecting by Modifying Existing Responses (PRIMER) is an on-going international multisite prospective study seeking to assess the impact of a range of socio structural factors on the risk that PWID initiate others into drug injecting. The methods used in the PRIMER study have been previously described [39]. In brief, PRIMER includes quantitative data from existing cohort studies of PWID to assess risks associated with their provision of injection initiation assistance. Because we sought to determine the potential impact of non-injection drug use among PWID in a high-risk, under-resourced setting, the present analysis was restricted to data from participants in the *Proyecto El Cuete IV* (ECIV) cohort in Tijuana, Mexico.

Study Sample and Recruitment

ECIV participants are community-recruited, with eligibility restricted to individuals who are over 18 years old, report recent injection drug use (i.e., in the last 6 months), and speak either Spanish or English. Written

consent is obtained from each participant prior to enrolment. All participants receive financial compensation for their time commitment.

Data Collection and Variable Definition

The PRIMER baseline was defined as the visit at which questions specific to the provision of injection initiation assistance were first introduced into the ECIV questionnaire. For most participants ($n = 475$), baseline interviews coincided with follow-up 7 (September 2014). However, some participants missed visit 7 and thus, the PRIMER questions were first introduced to them at follow-up 8 or later (29 at follow-up 8; 20 at follow-up 9; 5 at follow-up 10; and 3 at follow-up 11). At baseline and at 6-month follow-up intervals, participants completed interviewer-administered questionnaires on their involvement in providing injection initiation assistance, including specific experiences initiating others into injecting, motivations for doing so, the relationships between initiators and initiates, and participants' perceived risk of initiating others into injecting in the future. For the purpose of this study, ECIV follow-up 7 was translated to PRIMER visit 1. Longitudinal data from September 2014 (PRIMER visit 1) to August 2016 (PRIMER visit 5) were included in the analysis. The main outcome measure was defined as reporting the provision of injection initiation assistance in the past 6 months. The main independent variable of interest was defined as any recent (i.e., past 6 months) non-injection drug use. Further, non-injection and injection drug use in the past 6 months was stratified by drug type (i.e., heroin, cocaine, methamphetamine, and other opioids). Other independent variables considered in the analyses included age, gender, housing situation, and injection frequency.

Analysis

Cross-sectional analyses were performed at the PRIMER baseline. Univariate cross-tabulations along with Fisher's exact test were used to assess the association between baseline demographics and drug use characteristics, and the provision of recent injection initiation assistance.

To incorporate longitudinal data, we used generalized estimating equation (GEE) methods, which allow for the determination of independent associations between variables across follow-ups, while adjusting for within-subject correlation among participants who provide data

at multiple time points [40]. Participants providing data for at least one visit were included in the models. The dependent variable was defined as recent (i.e., past 6 months) provision of injection initiation at each visit (yes vs. no). The main independent variable of interest was recent non-injection drug use (yes vs. no) at each visit. We employed an a priori approach whereby variables assessing participants' socio-demographic (i.e., age, gender, and housing situation [stable vs. other]) and injection frequency (i.e., daily vs. less than daily vs. none) were included in the final multivariable model. First, we examined the independent impact of recent non-injection use of any drug on injection initiation assistance. We then carried out subanalyses wherein we developed multivariable GEE models to investigate the impact of recent non-injection use of specific types of drugs (i.e., heroin, cocaine, and methamphetamine) on the provision of injection initiation assistance.

All statistical analyses were performed using R statistical software (version 3.3.2).

Results

Baseline Data

Overall, study participants ($n = 534$) were predominantly male (62%, 329) and ranged in age from 21 to 67 years old (median = 40, interquartile range [IQR] = 35–47). At baseline, 14% ($n = 76$) of participants reported ever providing injection initiation assistance, while 4% ($n = 23$) participants reported initiating others in the past 6 months. The median number of initiates per initiator in the past 6 months was 2 (IQR = 1–3).

The majority of the participants (83%, 442) reported having recently injected at least one drug. The largest proportion of participants reported injecting heroin in the past 6 months (81%, 433), followed by methamphetamine (53%, 283) and cocaine (1%, 6), while no participant reported having recently injected opioids. The median number of years injecting was 20 (IQR = 13–26) and the majority of participants reported injecting daily (76%, 404).

Approximately one third of participants (33%, 178) reported having used at least one drug by non-injection recently. Methamphetamine was the most commonly used non-injection drug among participants in the past 6 months (32%, 169), followed by heroin (4%, 20) and cocaine (1%, 6). Methamphetamine was mostly

uniquely smoked (95%, 161), while heroin was mostly uniquely snorted (55%, 11), and half of non-injection cocaine users reported uniquely snorting it (50%, 3). Only one participant reported using opioids via non-injection in the last 6 months (by swallowing).

In univariate cross-tabulations, being man ($p = 0.046$) and having reported non-injection use of cocaine ($p = 0.024$) or opioids ($p = 0.043$) in the 6 months prior to baseline were associated with providing injection initiation assistance (Table 1).

Longitudinal Data

Across the study period (i.e., visit 1 to visit 5), providing injection initiation assistance in the last 6 months ranged

Table 1 Baseline characteristics stratified by injection initiation assistance in the past 6 months among a cohort of people who inject drugs in Tijuana, Mexico, 2014–2016 ($n = 532$)

Characteristic	Injection initiation assistance		<i>p</i> value
	No $n = 509$	Yes $n = 23$	
Age			
(Median, IQR)	40.5 (34.7–47.0)	39.2 (37.4–44.3)	0.931
Sex			
Women	201 (98.1%)	4 (2.0%)	0.046
Men	308 (94.2%)	19 (5.8%)	
Housing situation			
Stable housing	316 (95.8%)	14 (4.2%)	>0.999
Other	193 (95.5%)	9 (4.5%)	
Non-injection heroin			
No	490 (95.7%)	22 (4.3%)	0.594
Yes	19 (95.0%)	1 (5.0%)	
Non-injection cocaine			
No	505 (96.0%)	21 (4.0%)	0.024
Yes	4 (66.8%)	2 (33.3%)	
Non-injection crystal methamphetamine			
No	350 (96.2%)	14 (3.9%)	0.492
Yes	159 (94.6%)	9 (5.4%)	
Non-injection any drug			
No	342 (96.3%)	13 (3.7%)	0.365
Yes	167 (94.4%)	10 (5.7%)	
Injection drug use frequency			
None	89 (96.7%)	3 (3.3%)	0.927
Less than daily	36 (97.3%)	1 (2.7%)	
Daily	384 (95.3%)	19 (4.7%)	

Note: *IQR* interquartile range, $p < 0.05$ are italicized

from 1.64% in visit 3 ($n = 7$) to 4.84% in visit 1 ($n = 23$). In bivariate analysis, non-injection use of any drug was significantly associated with injection initiation for both visit 3 and visit 5 ($p = 0.009$) (Table 2).

In the GEE multivariable model, recent non-injection use of any drug was independently associated with providing injection initiation assistance (adjusted odds ratio [AOR] = 2.42; 95% confidence interval [CI] = 1.39–4.20). In subanalyses exploring the impact of specific types of non-injection drug use in separate GEE models, recent non-injection use of cocaine (AOR = 9.31, 95% CI = 3.98–21.78), heroin (AOR = 4.00, 95% CI = 1.88–8.54), and methamphetamine (AOR = 2.03, 95% CI = 1.16–3.55) were all significantly associated with providing injection initiation assistance (Table 3).

Discussion

Within a prospective cohort of PWID in Tijuana, 14% of participants reported having ever provided injection initiation assistance, and 4% reported initiating others in the 6 months prior to the PRIMER baseline. In multi-

Table 2 Univariate associations between non-injection drug use and injection initiation assistance in the past 6 months among a prospective cohort of people who inject drugs in Tijuana, Mexico, 2014–2016 ($n = 1987$ participant visits)

Any non-injection drug use	Injection initiation		<i>p</i> value
	No	Yes	
Visit 1 ($n = 475$)			
No	301 (95.9%)	13 (4.1%)	0.368
Yes	151 (93.8%)	10 (6.2%)	
Visit 2 ($n = 463$)			
No	312 (97.5%)	8 (2.5%)	>0.999
Yes	140 (97.9%)	3 (2.1%)	
Visit 3 ($n = 428$)			
No	275 (99.6%)	1 (0.4%)	0.009
Yes	146 (96.1%)	6 (4.0%)	
Visit 4 ($n = 371$)			
No	233 (97.9%)	5 (2.1%)	0.127
Yes	126 (94.7%)	7 (5.3%)	
Visit 5 ($n = 250$)			
No	170 (97.7%)	4 (2.3%)	0.009
Yes	68 (89.5%)	8 (10.5%)	

Note: $p < 0.05$ are italicized

Table 3 Adjusted odds ratios for non-injection of different drugs related to the provision of injection initiation assistance among people who inject drugs, in Tijuana, Mexico, 2014–2016 ($n = 1987$ participant visits)

	GEE model 1 (any non-injection drug use)		GEE model 2 (non-injection cocaine use)		GEE model 3 (non-injection heroin use)		GEE model 4 (non-injection methamphetamine use)	
	AOR	95% CI	AOR	95% CI	AOR	95% CI	AOR	95% CI
Any non-injection drug use ^a	2.42	[1.39–4.20]						
Non-injection cocaine use ^a			9.31	[3.98–21.78]				
Non-injection heroin use ^a					4.00	[1.88–8.54]		
Non-injection methamphetamine use ^a							2.03	[1.16–3.55]
Age	0.97	[0.94–1.00]	0.97	[0.95–1.00]	0.97	[0.94–1.00]	0.97	[0.94–1.00]
Male gender	2.5	[1.27–4.93]	2.13	[1.09–4.16]	2.22	[1.14–4.35]	2.40	[1.22–4.69]
Stable housing ^a	0.75	[0.46–1.23]	0.71	[0.44–1.16]	0.71	[0.44–1.15]	0.74	[0.45–1.21]
Injecting frequency: less than daily ^a	0.71	[0.12–4.04]	0.88	[0.17–4.64]	0.84	[0.17–4.08]	0.73	[0.13–4.14]
Injecting frequency: daily ^a	1.80	[0.74–4.38]	1.95	[0.79–4.81]	1.99	[0.82–4.86]	1.81	[0.74–4.41]

$p < 0.05$ are italicized

GEE generalized estimating equation, AOR adjusted odds ratio, CI confidence interval

^a In the past 6 months

variable analysis, multiple forms of non-injection drug use were associated with recently providing injection initiation assistance. These findings have implications for future research as well as efforts to prevent the entry of individuals into injection drug use.

Reporting recent non-injection use of cocaine or heroin was associated with a tenfold and fourfold increase, respectively, in the odds of reporting recent injection initiation assistance (though low frequencies of non-injection cocaine use in the sample contributed to wide confidence intervals), while non-injection use of methamphetamine was associated with a doubling of the odds. To our knowledge, the impact of non-injection drug use among potential initiators has not yet been extensively studied (the present study building on only one previous cross-sectional study by Bluthenthal and colleagues [34]). These findings provide further confirmation of the central role that non-injection drug use among PWID appears to play in increasing the risk that others will be initiated into drug injecting.

We posit that use of non-injection drugs by PWID may reflect their greater participation in social networks that include injection-naïve drug users. The interaction between PWID and non-injectors in drug-using settings may weaken social norms protective against injecting and may also provide injection-naïve drug users with access to sources of injection education and initiation assistance through increased exposure to injecting

practices. This suggests that efforts to prevent epidemics of drug-related harms (i.e., blood-borne disease transmission and overdose) may require approaches that seek to reduce the risk of injection initiation assistance posed by PWID, particularly those that engage in both injection and non-injection forms of drug use. In this regard, interventions such as medically supervised consumption facilities (i.e., for either non-injection [inhalation] or injection drug use) have been shown to reduce a range of drug-related harms [41–45]; our findings suggest that they may also reduce the risk that PWID expose injecting behaviors to others, and thereby disrupt population mixing between PWID and those at risk of initiating drug injecting. As such, future research should seek to clarify to what extent such facilities may support broader goals of preventing entry into injection drug use. Further, given the well-established role of PWID in initiating others into drug injecting [26, 32], our findings suggest that the development of interventions to prevent injection initiation should focus specifically on the subset of PWID who report both injection and non-injection drug use, as they likely act as a bridge population facilitating entry into drug injecting, and that programming such interventions for PWID who use cocaine by non-injection should be explored. Further research delineating the risk profile of such individuals will be required to optimize intervention development in this area.

Finally, we note that studies investigating injection initiation assistance in other settings have reported that PWID samples report initiating others in proportions ranging from 17 to 69% [26, 32–35]. While these differences may be attributed to variations in inclusion criteria, study designs, sampling techniques, and study settings, it is worth noting that the proportion of ECIV participants reporting lifetime history of initiating others is lower than Bryant's study (17%), which was limited to young and new injectors [35]. This suggests that ECIV study participants may initiate others at uniquely low levels. More research, including studies employing qualitative or mixed-methods designs, may be useful to investigate the context for these differences and their potential applicability to injection prevention goals.

Our study results should be viewed in light of some potential limitations typical of observational research among drug-using populations. First, study recruitment relied on non-randomized methods, and we therefore caution against generalization of findings to the broader population of PWID in Tijuana. Second, the survey questionnaire relied on self-reporting and, consequently, in addition to the possibility for recall bias, the social norms and stigma related to injection drug use in general and injection initiation in particular likely resulted in under-reporting on these topics [46, 47]. However, we know of no reason why this phenomenon may have differentially impacted participants who did and did not report non-injection drug use. Third, this is an ongoing prospective community-recruited study. As such, some participants may not have reached their last visit when we started analyzing the data. Fourth, this study focused on the specific effects of the use of individual drugs by non-injection. We note that a study conducted recently by Meacham and colleagues in the same setting suggested that poly-drug and poly-route users may represent specific subgroups with an increased risk of engaging in HIV risk behaviors [48]. This may underline the need for future research studies to assess whether these subgroups are at greater risk of providing injection initiation assistance.

Lastly, it is worth noting that the majority of existing longitudinal studies on injection initiation have been conducted in high-income settings (i.e., the Netherlands, Canada, and the USA) [36, 49, 50], characterized by relatively stable PWID populations that face fewer daily risks related to drug law enforcement compared with Tijuana [51–54]. For instance, during the spring of 2015, the municipal government in Tijuana undertook

a forced evacuation of the river canal encampment known as “*El Bordo*,” where many homeless PWID and other vulnerable populations such as recent deportees resided [55]. The evacuation was conducted by police raids and many of the canal residents, which included some ECIV participants, were placed in mandatory rehabilitation centers, prison, or have not been located.

In conclusion, this study reports on an independent association between non-injection drug use and the provision of injection initiation assistance observed among PWID in Tijuana, Mexico, an under-resourced setting characterized by a large and dynamic population of PWID. These findings have important implications for the development of interventional approaches to reduce injection initiation and related harms.

Acknowledgements Dan Werb is supported by a grant to the PRIMER study from the National Institute on Drug Abuse (NIDA DP2-DA040256-01) and by the Canadian Institutes of Health Research via a New Investigator Award. El Cuete IV is also supported by NIDA via a MERIT Award (R37 DA019829). C. Rafful was supported by a UC-MEXUS/CONACyT scholarship grant number 209407/313533, the UC MEXUS Dissertation grant number DI 15-42, and R25 DA026401.

References

1. UNODC. World Drug Report. May, 2016. 2016; <http://www.unodc.org/wdr2016/>. Accessed April 10, 2017
2. UNAIDS. Prevention gap report. July 11, 2016; <http://www.unaids.org/en/resources/documents/2016/prevention-gap>. Accessed April 10, 2017.
3. Ly KN, Xing J, Kleven RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. *Ann Intern Med*. 2012;156(4):271–8.
4. Mehta SH, McFall AM, Srikrishnan AK, et al. Morbidity and mortality among community-based people who inject drugs with a high hepatitis C and human immunodeficiency virus burden in Chennai, India. *Open Forum Infect Dis*. 2016;3(3):ofw121.
5. Lumberras B, Jarrin I, del Amo J, et al. Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: *differences before and after HAART*. *AIDS*. 2006;20(1):111–6.
6. Rockstroh JK. Influence of viral hepatitis on HIV infection. *J Hepatol*. 2006;44(1 Suppl):S25–7.
7. Lloyd-Smith E, Wood E, Zhang R, Tyndall MW, Montaner JS, Kerr T. Risk factors for developing a cutaneous injection-related infection among injection drug users: a cohort study. *BMC Public Health*. 2008;8:405.

8. Millar B, Moore J. Emerging issues in infective endocarditis. *Emerg Infect Dis J* 2004;Volume 10.
9. Milloy MJ, Kerr T, Tyndall M, Montaner J, Wood E. Estimated drug overdose deaths averted by North America's first medically-supervised safer injection facility. *PLoS One*. 2008;3(10):e3351.
10. Vlahov D, Fuller CM, Ompad DC, Galea S, Des Jarlais DC. Updating the infection risk reduction hierarchy: preventing transition into injection. *J Urban Health*. 2004;81(1):14–9.
11. Werb D, Garfein R, Kerr T, et al. A socio-structural approach to preventing injection drug use initiation: rationale for the PRIMER study. *Harm Reduct J*. 2016;13(1):25.
12. Bluthenthal RN, Kral AH. Next steps in research on injection initiation incidence and prevention. *Addiction*. 2015;110(8):1258–9.
13. Debeck K, Kerr T, Marshall BD, Simo A, Montaner J, Wood E. Risk factors for progression to regular injection drug use among street-involved youth in a Canadian setting. *Drug Alcohol Depend*. 2013;133(2):468–72.
14. van Ameijden EJ, van den Hoek JA, Hartgers C, Coutinho RA. Risk factors for the transition from noninjection to injection drug use and accompanying AIDS risk behavior in a cohort of drug users. *Am J Epidemiol*. 1994;139(12):1153–63.
15. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. *Am J Public Health*. 1996;86(5):655–61.
16. Cameiro M, Fuller C, Doherty MC, Vlahov D. HIV prevalence and risk behaviors among new initiates into injection drug use over the age of 40 years old. *Drug Alcohol Depend*. 1999;54(1):83–6.
17. Kral AH, Lorvick J, Edlin BR. Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco. *J Acquir Immune Defic Syndr*. 2000;24(2):162–7.
18. Doherty MC, Garfein RS, Monterroso E, Brown D, Vlahov D. Correlates of HIV infection among young adult short-term injection drug users. *AIDS*. 2000;14(6):717–26.
19. Strike C, Rotondi M, Kolla G, et al. Interrupting the social processes linked with initiation of injection drug use: results from a pilot study. *Drug Alcohol Depend*. 2014;137:48–54.
20. Brouwer KC, Case P, Ramos R, et al. Trends in production, trafficking, and consumption of methamphetamine and cocaine in Mexico. *Subst Use Misuse*. 2006;41(5):707–27.
21. Magis-Rodriguez C, Brouwer KC, Morales S, et al. HIV prevalence and correlates of receptive needle sharing among injection drug users in the Mexican-U.S. border city of Tijuana. *J Psychoactive Drugs*. 2005;37(3):333–9.
22. Strathdee SA, Lozada R, Pollini RA, et al. Individual, social, and environmental influences associated with HIV infection among injection drug users in Tijuana, Mexico. *J Acquir Immune Defic Syndr*. 2008;47(3):369–76.
23. Strathdee SA, Magis-Rodriguez C. Mexico's evolving HIV epidemic. *JAMA*. 2008;300(5):571–3.
24. Werb D, Buxton J, Shoveller J, Richardson C, Rowell G, Wood E. Interventions to prevent the initiation of injection drug use: a systematic review. *Drug Alcohol Depend*. 2013;133(2):669–76.
25. Bryant J, Treloar C. The gendered context of initiation to injecting drug use: evidence for women as active initiates. *Drug Alcohol Rev*. 2007;26(3):287–93.
26. Crofts N, Louie R, Rosenthal D, Jolley D. The first hit: circumstances surrounding initiation into injecting. *Addiction*. 1996;91(8):1187–96.
27. Doherty MC, Garfein RS, Monterroso E, Latkin C, Vlahov D. Gender differences in the initiation of injection drug use among young adults. *J Urban Health*. 2000;77(3):396–414.
28. Goldsamt LA, Harocopos A, Kobrak P, Jost JJ, Clatts MC. Circumstances, pedagogy and rationales for injection initiation among new drug injectors. *J Community Health*. 2010;35(3):258–67.
29. Harocopos A, Goldsamt LA, Kobrak P, Jost JJ, Clatts MC. New injectors and the social context of injection initiation. *Int J Drug Policy*. 2009;20(4):317–23.
30. Rahimi-Movaghar A, Amin-Esmaeili M, Shadloo B, Noroozi A, Malekinejad M. Transition to injecting drug use in Iran: a systematic review of qualitative and quantitative evidence. *Int J Drug Pol*. 2015;26(9):808–19.
31. Roy E, Haley N, Leclerc P, Cedras L, Blais L, Boivin JF. Drug injection among street youths in Montreal: predictors of initiation. *J Urban Health*. 2003;80(1):92–105.
32. Rotondi NK, Strike C, Kolla G, et al. Transition to injection drug use: the role of initiators. *AIDS Behav*. 2014;18(3):486–94.
33. Kermode M, Longleng V, Singh BC, Hocking J, Langkham B, Crofts N. My first time: initiation into injecting drug use in Manipur and Nagaland, north-east India. *Harm Reduct J*. 2007;4:19.
34. Bluthenthal RN, Wenger L, Chu D, Quinn B, Thing J, Kral AH. Factors associated with initiating someone into illicit drug injection. *Drug Alcohol Depend*. 2014;144:186–92.
35. Bryant J, Treloar C. Initiators: an examination of young injecting drug users who initiate others to injecting. *AIDS Behav*. 2008;12(6):885–90.
36. Werb D, Kerr T, Buxton J, et al. Crystal methamphetamine and initiation of injection drug use among street-involved youth in a Canadian setting. *CMAJ*. 2013;185(18):1569–75.
37. Young AM, Havens JR. Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: a cross-sectional comparison and retrospective survival analysis. *Addiction*. 2012;107(3):587–96.
38. DeBeck K, Wood E, Dong H, et al. Non-medical prescription opioid use predicts injection initiation among street-involved youth. *Int J Drug Policy*. 2016;34:96–100.
39. Werb D, Garfein RS, Kerr T, et al. A socio-structural approach to preventing injection drug use initiation: rationale for the PRIMER study. *Harm Reduct J*. 2016;13(1):25.
40. Zeger SL, Liang K-Y. Longitudinal data analysis for discrete and continuous outcomes. *Biometrics*. 1986;42(1):121–30.
41. Kerr T, Tyndall M, Li K, Montaner J, Wood E. Safer injection facility use and syringe sharing in injection drug users. *Lancet*. 2005;366(9482):316–8.
42. Wood E, Tyndall MW, Montaner JS, Kerr T. Summary of findings from the evaluation of a pilot medically supervised safer injecting facility. *CMAJ*. 2006;175(11):1399–404.
43. Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility:

- a retrospective population-based study. *Lancet*. 2011;377(9775):1429–37.
44. Kimber J, Dolan K, van Beek I, Hedrich D, Zurhold H. Drug consumption facilities: an update since 2000. *Drug Alcohol Rev*. 2003;22(2):227–33.
 45. Lloyd C, Hunt N. Drug consumption rooms: an overdue extension to harm reduction policy in the UK? *Int J Drug Policy*. 2007;18(1):5–9.
 46. Small W, Fast D, Krusi A, Wood E, Kerr T. Social influences upon injection initiation among street-involved youth in Vancouver Canada: a qualitative study. *Subst Abuse Treat Prev Policy*. 2009;4:8.
 47. Rivera AV, DeCuir J, Crawford ND, Amesty S, Lewis CF. Internalized stigma and sterile syringe use among people who inject drugs in New York City, 2010–2012. *Drug Alcohol Depend*. 2014;144:259–64.
 48. Meacham MC, Roesch SC, Strathdee SA, Lindsay S, Gonzalez-Zuniga P, Gaines TL. Latent classes of polydrug and polyroute use and associations with human immunodeficiency virus risk behaviours and overdose among people who inject drugs in Tijuana, Baja California, Mexico. *Drug Alcohol Rev*. 2017.
 49. Neaigus A, Gyarmathy VA, Miller M, Frajzyngier VM, Friedman SR, Jarlais DCD. Transitions to injecting drug use among noninjecting heroin users. *J Acquir Immune Defic Syndr*. 2006;41(4):493–503.
 50. Buster MCA, Witteveen E, Prins M, van Ameijden EJC, Schippers G, Krol A. Transitions in drug use in a new generation of problem drug users in Amsterdam: a 6-year follow-up study. *Eur Addict Res*. 2009;15(4):179–87.
 51. Strathdee SA, Fraga WD, Case P, et al. “Vivo para consumirla y la consumo para vivir” [“I live to inject and inject to live”]: high-risk injection behaviors in Tijuana, Mexico. *J Urban Health*. 2005;82(3 Suppl 4):iv58–73.
 52. Pollini RA, Brouwer KC, Lozada RM, et al. Syringe possession arrests are associated with receptive syringe sharing in two Mexico-US border cities. *Addiction*. 2008;103(1):101–8.
 53. Miller CL, Firestone M, Ramos R, et al. Injecting drug users’ experiences of policing practices in two Mexican-U.S. border cities: public health perspectives. *Int J Drug Policy*. 2008;19(4):324–31.
 54. Werb D, Strathdee SA, Vera A, et al. Spatial patterns of arrests, police assault and addiction treatment center locations in Tijuana, Mexico. *Addiction*. n111(7):1246–56.
 55. Guerrero J. Tijuana mandates drug treatment for hundreds of homeless. *KPBS* April 13, 2015. <http://www.kpbs.org/news/2015/apr/13/tijuana-homeless-get-compulsory-treatment/>. Accessed April 10, 2017.